This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B20.5 (HIV disease resulting in other mycoses) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration) |
| B. Synonyms | HIV-associated other mycoses; HIV-associated cryptococcosis; HIV-associated histoplasmosis; HIV-associated aspergillosis; HIV-associated coccidioidomycosis; AIDS-associated non-Candida mycoses |
| C. Adult onset | Likelihood of first onset in adulthood: Very high — Cryptococcal meningitis (CD4 <100/μL), histoplasmosis, and aspergillosis all occur mainly in adult patients with HIV whose immunosuppression has progressed, and community-acquired fungal infections in particular are concentrated in adults. |
| 1. History | 1955: description of cryptococcal meningitis → late 1970s: frequent in patients with end-stage cancer → 1981: with the AIDS epidemic, large-scale surge in cryptococcosis and histoplasmosis → 1992: amphotericin B treatment established as standard → 1996: sharp decline in incidence in developed countries after ART → 2013: WHO cryptococcal diagnosis and treatment guidelines published → 2022: recommendation to expand access to flucytosine. |
| 2. Causes | Main fungi: Cryptococcus neoformans/gattii (meningitis, lung), Histoplasma capsulatum (disseminated), Aspergillus fumigatus/flavus (invasive pulmonary aspergillosis), Coccidioides immitis/posadasii (highly endemic areas), Talaromyces marneffei (Southeast Asia). The risk of disseminated mycosis is highest at CD4 <100/μL. |
| 3. Genetics | IFNGR1/IFNGR2, STAT1, IRF8 variants → deficient interferon-γ signaling → increased susceptibility to mycobacteria and fungi. CARD9 variants → susceptibility related to dephosphorylation (Candida and other fungi). Dectin-1 genotype → reduced fungal recognition. The polysaccharide capsule of C. neoformans is a key virulence factor for suppressing complement activation and resisting phagocytosis. |
| 4. General epidemiology | Cryptococcal meningitis: 223,100 cases per year and 181,100 deaths among patients with HIV worldwide (2014 estimate). Concentrated in sub-Saharan Africa. Histoplasmosis: 3rd-5th cause of AIDS-defining illness among patients with HIV in the Americas. Invasive aspergillosis: high risk when CD4 <50/μL is accompanied by neutropenia. |
| 5. Epidemiology in Korea | Cryptococcal meningitis in Korean patients with HIV is a rare but fatal AIDS complication. Incidence has decreased with improved access to ART. Histoplasma and Coccidioides should be considered in patients with a history of travel to or residence in endemic areas abroad. Talaromycosis (T. marneffei) has been reported in patients with HIV who stayed in Southeast Asia. |
| 6. Pathophysiology | Cryptococcus: pulmonary inhalation → polysaccharide capsule → resistance to phagocytosis → hematogenous dissemination → crossing the blood-brain barrier (Trojan horse mechanism) → meningitis. Histoplasma: pulmonary inhalation → survival within macrophages → dissemination when immunosuppressed. Aspergillus: alveolar inhalation → absence of neutrophils and low CD4 → vascular invasion · pulmonary infarction. Elevated intracranial pressure in cryptococcal meningitis is a major cause of optic nerve damage and brain herniation. |
| 7. Clinical features | Cryptococcal meningitis: headache, fever, altered consciousness (gradual progression over several weeks), mild neck stiffness, visual field abnormalities (papilledema). Histoplasmosis: fever, weight loss, hepatosplenomegaly, pancytopenia (disseminated). Aspergillosis: fever, cough, chest pain, hemoptysis. Talaromycosis: fever, skin lesions (central necrotic papules), lymphadenopathy, hepatomegaly. |
| 8. Tests and diagnosis | Cryptococcus: serum and CSF cryptococcal antigen (lateral flow assay, sensitivity >95%), CSF India ink stain, culture (Sabouraud). Histoplasma: urine and serum antigen (MVista EIA), culture (BL3 facility), tissue GMS. Aspergillus: serum galactomannan (GM), beta-D-glucan, chest CT (halo sign), bronchial lavage culture and PCR. CSF opening pressure measurement: essential in cryptococcal meningitis. |
| 9. Treatment | Cryptococcal meningitis: induction therapy — lipid formulation of amphotericin B + flucytosine for 2 weeks; consolidation — fluconazole 400mg/day for 8 weeks; maintenance — fluconazole 200mg/day (stop when CD4 recovers). Therapeutic lumbar puncture for elevated intracranial pressure. Histoplasma (moderate to severe): liposomal amphotericin B → itraconazole. Aspergillus: voriconazole or isavuconazole first-line; salvage therapy with echinocandin combination. |
| 10. Prognosis | Cryptococcal meningitis: 100% fatal without appropriate treatment. Even with optimal treatment, the 10-week mortality is 20-30% (ACTA study in Africa). Risk of a sudden rise in intracranial pressure if IRIS occurs. Prognosis improves after CD4 recovery with ART. Histoplasmosis: recurrence can be prevented with itraconazole maintenance therapy. Aspergillosis: mortality 30-70% (in severe immunosuppression). |
| 11. Latest findings | WHO 2022 cryptococcal meningitis recommendations: recommend a 'short-course induction regimen' of short-term high-dose amphotericin B (1 week) + flucytosine followed by a switch to fluconazole, reducing toxicity. Expanded access to oral flucytosine. Monitoring itraconazole blood levels to optimize maintenance treatment of histoplasmosis. Increasing experience with isavuconazole in HIV mycoses. Wider deployment of point-of-care testing with rapid fungal antigen tests (LFA). |
| 12. Prevention | Primary prevention: maintain CD4 >100/μL with ART. Cryptococcal endemic areas (sub-Saharan Africa): if CD4 <100/μL, screen for serum cryptococcal antigen and give preemptive fluconazole treatment if positive. Histoplasma endemic areas: consider itraconazole primary prophylaxis. Avoid exposure to pigeon habitats and construction-site dust. Secondary prevention: maintain fluconazole/itraconazole for cryptococcus and histoplasma, stopping when CD4 recovers. |
| 13. References | Bratton EW et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant and 9 other articles |
Cryptococcosis was first described by Otto Busse in 1894, and the form of central nervous system infection (meningitis) was clinically established in 1955. In the 1970s it occurred mainly in patients with end-stage cancer and in steroid users. When the HIV/AIDS epidemic began in 1981, cryptococcal meningitis, histoplasmosis, and coccidioidomycosis increased sharply in patients with AIDS and came to be recognized as major AIDS-defining illnesses.
Histoplasmosis was first described by Samuel Darling in Panama in 1905. In the 1940s, the Mississippi and Ohio River valleys of the United States were identified as the main endemic area. After the AIDS epidemic, disseminated histoplasmosis became the 3rd to 5th cause of AIDS-defining illness among patients with HIV in this region.
In treatment history, amphotericin B in 1992 was established as the standard treatment for cryptococcal meningitis, and fluconazole combination and maintenance therapy were subsequently established. After the introduction of ART in 1996, incidence dropped sharply in developed countries, but in sub-Saharan Africa, where access to ART is limited, cryptococcal meningitis is still a leading cause of death. In 2022, the WHO revised the treatment guidelines for cryptococcal meningitis and recommended short-course induction therapy and expanded access to flucytosine.
B20.5 encompasses all HIV-associated mycoses except B20.4 (candidiasis), and the clinically important fungi differ by region.
Cryptococcus neoformans var. grubii (serotype A, worldwide) and var. neoformans (serotype D, Europe), C. gattii (serotype B/C, tropical and subtropical; can also infect immunocompetent persons). Inhaled from the environment, such as pigeon droppings. The risk of disseminated meningitis is highest at CD4 <100/μL.
Histoplasma capsulatum: Spores are inhaled from soil contaminated with bird or bat droppings, caves, and building demolition sites. Endemic in the central United States (Ohio/Mississippi valleys), Central America, the Caribbean, South America, and parts of Africa. The disseminated form occurs at CD4 <150/μL.
Aspergillus fumigatus (most common), A. flavus, A. terreus (amphotericin resistant). Ubiquitous environmental filamentous fungi. The risk of aspergillosis is low with HIV alone, but increases when CD4 <50/μL is accompanied by neutropenia, steroids, or underlying lung disease.
Host genetic factors influence susceptibility to fungi. Variants in IFNGR1, IFNGR2, STAT1, IRF8 disturb the interferon-γ (IFN-γ) signaling pathway and reduce cellular immunity against mycobacteria and fungi (especially Cryptococcus). Even without these variants, HIV-induced CD4 depletion causes a practically equivalent functional deficiency.
Loss-of-function variants of the CARD9 gene cause deficient dephosphorylation (dectin) signaling against Candida and other fungi, raising the risk of recurrent mycoses independent of HIV. The Y238X polymorphism of Dectin-1 (CLEC7A) is common in Europeans and increases fungal susceptibility through reduced β-glucan recognition.
Fungal virulence: The polysaccharide capsule (glucuronoxylomannan, GXM) of C. neoformans plays a key role in suppressing complement activation, resisting opsonization, and surviving within phagocytes. The degree of polymerization and acetylation of GXM differs by strain and affects virulence. The laccase enzyme is involved in black melanin pigment synthesis → defense against reactive oxygen species.
Cryptococcal meningitis is estimated to occur in about 223,100 patients with HIV per year worldwide, with about 181,100 deaths (Rajasingham 2017). This accounts for about 15% of HIV-related deaths and is concentrated in sub-Saharan Africa and Southeast Asia.
Histoplasmosis is the 3rd to 5th cause of AIDS-defining illness in patients with HIV in highly endemic areas. In the Mississippi River valley of the United States and the Caribbean, 5-25% of patients with CD4 <150/μL experience disseminated histoplasmosis.
Invasive aspergillosis is rare in patients with HIV alone (incidence <1%), and the risk rises when neutropenia, steroid use, or underlying lung disease is present. Talaromycosis is the 3rd most common opportunistic infection in patients with HIV in Southeast Asia and occurs mainly at CD4 <100/μL.
In Korean patients with HIV, cryptococcal meningitis is a rare but fatal AIDS complication, occurring mainly in late presenters with HIV and CD4 <50/μL. Its frequency has decreased with the improved ART treatment rate in Korea (over 90% in the 2020s), but cases arising during the initial hospitalization of late-diagnosed patients are still observed.
Histoplasmosis, coccidioidomycosis, and talaromycosis are rarely reported in Korea, mainly in patients with HIV who have a history of travel to or residence in endemic areas abroad (Southeast Asia, Central and South America, southwestern United States). Domestic cases of talaromycosis have been reported in patients with HIV who returned from Thailand and Vietnam.
Invasive aspergillosis is very rare in Korean patients with HIV and is limited to cases accompanied by chemotherapy, organ transplantation, or steroids. In the Korean setting, the most clinically important fungus in B20.5 is Cryptococcus, and it should be included at the top of the differential diagnosis in patients with HIV who have headache, fever, and altered consciousness in a state of late CD4 decline.
Desiccated yeast or spores from the environment are inhaled into the lungs → phagocytosed by pulmonary macrophages. In immunocompetent persons, the organisms are walled off by granuloma formation. In HIV immunosuppression → the polysaccharide capsule (GXM) suppresses complement activation and the Th1 response, resisting phagocytosis → hematogenous dissemination → crossing the blood-brain barrier. Mechanisms of crossing the blood-brain barrier: entry into the central nervous system after survival within phagocytes ('Trojan horse'), or direct penetration of cerebral vascular endothelial cells.
Within the central nervous system, the organisms proliferate while the glial inflammatory response is suppressed → formation of highly viscous cysts → elevated intracranial pressure (increased ICP). Elevated intracranial pressure is a major cause of optic nerve damage and brain herniation.
Inhalation of small spores (microconidia) → phagocytosis by alveolar macrophages → conversion to the 37°C yeast form within macrophages → under normal immunity, suppressed by granuloma formation mediated by CD4+ T cells and IFN-γ. In HIV immunosuppression → reduced macrophage function → systemic dissemination via lymph nodes and the bloodstream → involvement of liver, spleen, bone marrow, skin, and brain.
Inhalation of conidia → reaching the alveoli → normal immunity: killing by alveolar macrophages and neutrophils. Immunosuppression: hyphal germination and growth → vascular invasion → pulmonary infarction and cavity formation → hematogenous dissemination (brain, heart, kidney).
Typically headache, fever, and malaise that progress slowly over several weeks. Neck stiffness may be mild or absent compared with bacterial meningitis, so diagnostic delay is common. With progression, clouding of consciousness, visual field abnormalities (papilledema), and cranial nerve palsies. Pulmonary cryptococcosis: fever, cough, nodular lung opacities.
Fever, chills, weight loss, and generalized weakness progress over several weeks. Hepatosplenomegaly, pancytopenia (bone marrow involvement), lymphadenopathy. Skin lesions (oral ulcers, skin nodules). Respiratory symptoms take the form of interstitial pulmonary infiltrates. Markedly elevated LDH and ferritin.
Fever, cough, chest pain, hemoptysis. Chest CT: halo sign (early — hemorrhagic opacity around the hyphae), air crescent sign (late). Cerebral aspergillosis: seizures, altered consciousness.
Fever, weight loss, skin lesions (central necrotic papules — umbilicated papules, similar to molluscum contagiosum), lymphadenopathy, hepatomegaly, cough.
Serum and CSF cryptococcal antigen test (CrAg): The lateral flow assay (LFA), with sensitivity >95% and specificity >97%, is the standard diagnostic method. Lumbar puncture: measure opening pressure (normal 10-20 cmH₂O; perform therapeutic puncture if >25 cmH₂O), CSF cell and chemistry tests, India ink stain, CrAg, fungal culture. CSF findings: mild or no cell increase, elevated protein, normal or decreased glucose.
Urine Histoplasma antigen (MVista EIA): Sensitivity 90-95% in the disseminated form. Serum antigen is also used. Blood, bone marrow, and tissue culture (Histoplasma is biosafety level 3; a BL3 facility is required). GMS (Gomori methenamine silver) stain of tissue biopsy: small intracellular yeasts are identified.
Serum galactomannan (GM): Sensitivity 65-80% (immunocompromised patients). Beta-D-glucan: nonspecific but an adjunct to diagnosis. Chest CT: halo sign (early), air crescent sign (late). Bronchoalveolar lavage (BAL) culture and PCR. Confirmation: identification of hyphal invasion on tissue biopsy.
Culture or tissue staining of blood, bone marrow, or skin biopsy (GMS, PAS — dividing yeasts with characteristic septa). Urine and serum antigen tests (some reference laboratories).
Induction (2 weeks): lipid formulation of amphotericin B (liposomal AmB, 3mg/kg/day IV) + flucytosine (5-FC, 100mg/kg/day in 4 divided doses orally). Monitor for nephrotoxicity and bone marrow suppression. Consolidation (8 weeks): fluconazole 400-800mg/day orally. Maintenance (12 months or until CD4 recovery): fluconazole 200mg/day. Intracranial pressure >25 cmH₂O: daily therapeutic lumbar puncture (remove 20-30mL of CSF) — continue until pressure normalizes; consider ventricular drainage if lumbar puncture is not possible. Start ART 2-10 weeks after meningitis treatment (to prevent immune reconstitution cerebral cryptococcal IRIS).
Induction: liposomal amphotericin B 3mg/kg/day, 1-2 weeks. Maintenance/consolidation: itraconazole 200mg twice daily, 12 months. Mild: itraconazole alone. Monitor itraconazole blood levels (target 0.5-2 μg/mL). Drug interactions: caution regarding metabolic interactions of itraconazole with rifampin and some PIs.
First-line: voriconazole 6mg/kg twice (loading) → 4mg/kg twice daily IV. Or isavuconazole. Salvage therapy: liposomal AmB, echinocandin combination. Monitor voriconazole blood levels (target 1-5.5 μg/mL; to prevent hepatotoxicity and neurotoxicity).
Severe: amphotericin B for 2 weeks → itraconazole 200mg twice daily. Mild: itraconazole. Maintenance treatment: until CD4 recovery.
Cryptococcal meningitis is 100% fatal without appropriate treatment, and even with optimal treatment the 10-week mortality reaches 20-30% (ACTA study, sub-Saharan Africa). Most deaths are due to diagnostic delay, failure to control intracranial pressure, and IRIS (immune reconstitution inflammatory response) after ART initiation. Prognosis improves markedly after CD4 recovers to 200/μL or higher with ART.
Histoplasmosis can be prevented from recurring with itraconazole maintenance therapy after appropriate amphotericin B induction, and survival is high when combined with ART. However, recurrence due to subtherapeutic itraconazole blood levels is a clinical problem.
The mortality of invasive aspergillosis reaches 30-70% in patients with severe immunosuppression (CD4 <50/μL + neutropenia). Survival has improved since the era of voriconazole treatment, but diagnostic delay is the most important prognostic factor.
WHO 2022 cryptococcal meningitis recommendations: Showed that short-course induction therapy (1 week of high-dose AmB + flucytosine → switch to fluconazole) is as effective as the standard 2-week induction regimen while reducing toxicity. In particular, expanding access to oral flucytosine in low-income countries is a key recommendation. Fluconazole-alone induction without flucytosine is inferior and is not recommended.
Isavuconazole is drawing attention as an alternative to voriconazole in aspergillosis and rare mycoses, and has the advantage of fewer neurotoxicity and photosensitivity adverse effects. Olorofim (a dihydroorotate dehydrogenase inhibitor) showed promising results in a phase 2 trial in azole-resistant Aspergillus.
Deployment of point-of-care testing with the cryptococcal lateral flow antigen test (CrAg LFA) is expanding in low-income countries, improving early diagnosis rates. A point-of-care LFA version of the Histoplasma urine antigen test is also being clinically validated in South America.
As with candidiasis, the most effective prevention is maintaining the CD4 count through ART. At CD4 >200/μL, the risk of cryptococcosis, histoplasmosis, and aspergillosis decreases markedly. Routine primary prophylaxis with fluconazole is not recommended in developed countries because of concern about resistance.
In cryptococcal endemic areas such as sub-Saharan Africa, serum CrAg screening is performed in patients with HIV and CD4 <100/μL, and if positive, preemptive fluconazole treatment (800mg/day for 2 weeks, then 400mg/day for 8 weeks, then 200mg/day) is recommended regardless of the presence of symptoms (WHO 2022). This approach is not essential in Korea, but CrAg screening can be considered in late-diagnosed patients with HIV (CD4 <100/μL).
Avoid exposure to pigeon habitats and bird droppings (Cryptococcus), avoid building demolition and cave exploration (Histoplasma, Coccidioides), and wear an N95 mask when exposed to construction-site dust (Aspergillus). Patients with HIV staying in Southeast Asia should avoid exposure to bamboo forests and caves (Talaromyces).
Cryptococcus: fluconazole 200mg/day → stop if CD4 >200/μL is maintained for 3-6 months or more. Histoplasma: itraconazole 200mg/day → stop if CD4 >150/μL + antigen turns negative. Aspergillus: evidence for secondary prevention is limited; individualized decision in patients at high risk of severe recurrence.